arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Apyx Medical Corp

APYX
$3.06 ▲ +0.47 (+17.95%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
68 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
21
Health
Poor
Bearish
auto_awesome

Analytical Summary

Apyx Medical Corp faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $134.2M
Dividend Yield —
Revenue Growth 22.1% ↘
Op. Margin -13.0% ↘
ROIC -3.9% ↘
FCF / Share $-0.08 ↘
Trailing P/E —
Price / Book 12.1x
FCF Yield —
Debt / Equity 3.52
info Valuation on last close. End-of-day price, Nov 5, 2026.

68-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$13.88M
↑ +22.1% —
Net Income Profit after all expenses
$-3.24M
↑ +14.2% —
Operating Margin Operating profit as % of sales
-13.0%
↓ -78.3% 14th
FCF / Share Free cash flow per share
$-0.08
↓ -461.3% —
Long-Term Debt Long-term obligations
$37.50M
— 0.0% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
11
Returns ↓
12
Financial Health ↑
27
Cash Quality ↑
55

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 18 years · 68 quarters